Related Experiment Videos
Invasive Trichosporon beigelii infection in immunosuppressed rats
A Dörlemann1, H Listemann, F Iglauer
1Bernhard-Nocht Institute for Tropical Medicine (BNI), Clinical Medicine Section, Hamburg, Germany.
Mycoses
|March 1, 1994
Summary
Fulminant systemic mycoses, primarily Trichosporon beigelii, complicated Pneumocystis carinii pneumonia drug trials in immunosuppressed rats. Contaminated inoculums highlight the need for better animal models for invasive fungal infections in immunocompromised patients.
Area of Science:
- Medical Mycology
- Immunology
- Infectious Diseases
Background:
- Fulminant systemic mycoses are severe complications in immunocompromised individuals.
- Pneumocystis carinii pneumonia (PCP) treatment often involves immunosuppression, increasing susceptibility to opportunistic infections.
- Trichosporon beigelii is an emerging fungal pathogen in immunocompromised hosts.
Purpose of the Study:
- To investigate the development of systemic mycoses as complications in an animal model of Pneumocystis carinii pneumonia.
- To identify the causative fungal agent and its source of infection.
- To assess the suitability of this model for studying invasive fungal infections in immunocompromised states.
Main Methods:
- Rats were immunosuppressed using corticosteroids and a low-protein diet.
- Transtracheal inoculation with homogenized pulmonary tissue from a rat with pneumocystosis was performed.
- Fungal cultures and identification were conducted on infected rats.
Main Results:
- Secondary invasive mycosis was observed in 56 out of 59 (95%) rats.
- Trichosporon beigelii was identified as the predominant causative agent.
- A contaminated Pneumocystis inoculum was identified as the source of fungal infection.
Conclusions:
- The study successfully established a rat model for studying secondary invasive mycoses in the context of Pneumocystis carinii pneumonia.
- Contamination of inoculums poses a significant risk in animal model development.
- This model may aid in the development of strategies to combat invasive fungal infections in immunocompromised patients.